Circadian's continuing clinical development evolution: closer to commercial market (11:59)
Circadian Technologies Limited (ASX:CIR), CEO & MD, Robert Klupacs, talks about applications for its VGX-100 therapy in the treatment of a range of solid tumours, its phase 1 & 2 clinical program and partnerships for commercialisation. 20/12/11

























